IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gerhard Siemeister et al.

To be assigned

Group Art Unit:

Serial No.:

Examiner:

Filed: Herewith

For: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND

THEIR USE

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE CLAIMS:

- (Amended) Pharmaceutical compositions according to claim 1 which are intended for simultaneous or separate sequential therapeutical application.
- 10. (Amended) Pharmaceutical compositions according to claim 1 which comprise as compound I at least one of
 - a) compounds which inhibit receptor tyrosine kinase activity,
 - b) compounds which inhibit ligand binding to receptors,
 - c) compounds which inhibit activation of intracellular signal pathways of the receptors,